BIVICTRIX THERAPEUTICS PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.5 GBX | 0.00% |
|
0.00% | +9.52% |
| 17/04 | Bivictrix granted FDA orphan drug status for rare cancer treatment | AN |
| 17/04 | BiVictriX Wins US FDA's Orphan Drug Status for Blood Cancer Treatment | MT |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Capitalization 1 | 19.5 | 11.24 | 9.49 | 9.49 | - |
| Enterprise Value (EV) 1 | 19.5 | 8.06 | 20.25 | 38.39 | 36.69 |
| P/E ratio | -4.9 x | -4.5 x | -0.65 x | -0.45 x | 2.62 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | 0.95 x |
| EV / Revenue | - | - | - | - | 3.67 x |
| EV / EBITDA | - | -2.85 x | -1.72 x | -2.13 x | 30.9 x |
| EV / FCF | - | - | - | - | - |
| FCF Yield | - | - | - | - | - |
| Price to Book | - | - | - | - | - |
| Nbr of stocks (in thousands) | 66,115 | 66,115 | 82,526 | 82,526 | - |
| Reference price 2 | 0.2950 | 0.1700 | 0.1150 | 0.1150 | 0.1150 |
| Announcement Date | 07/03/22 | 30/03/23 | - | - | - |
1GBP in Million2GBP
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | 10 |
| EBITDA 1 | - | -2.824 | -11.8 | -18.04 | 1.188 |
| EBIT 1 | - | -2.975 | -12.21 | -18.48 | 0.718 |
| Operating Margin | - | - | - | - | 7.18% |
| Earnings before Tax (EBT) 1 | - | -2.971 | -12.2 | -18.6 | 0.431 |
| Net income 1 | -2.34 | -2.497 | -11.74 | -17.04 | 2.905 |
| Net margin | - | - | - | - | 29.05% |
| EPS 2 | -0.0602 | -0.0378 | -0.1780 | -0.2580 | 0.0439 |
| Free Cash Flow | - | - | - | - | - |
| FCF margin | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - |
| Announcement Date | 07/03/22 | 30/03/23 | - | - | - |
1GBP in Million2GBP
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | 10.8 | 28.9 | 27.2 |
| Net Cash position 1 | - | 3.18 | - | - | - |
| Leverage (Debt/EBITDA) | - | - | -0.9119 x | -1.602 x | 22.89 x |
| Free Cash Flow | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - |
| Cash Flow per Share 2 | - | -0.0400 | -0.1800 | -0.2700 | - |
| Capex 1 | - | - | 0.22 | 0.24 | 0.25 |
| Capex / Sales | - | - | - | - | 2.5% |
| Announcement Date | 07/03/22 | 30/03/23 | - | - | - |
1GBP in Million2GBP
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.115
GBP
Average target price
0.66
GBP
Spread / Average Target
+473.91%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +9.52% | 11.86M | |
| +23.37% | 46.71B | |
| +48.83% | 41.8B | |
| -0.94% | 41.52B | |
| -5.86% | 29.55B | |
| +11.29% | 25.78B | |
| -20.92% | 19.26B | |
| +3.20% | 12.14B | |
| -2.67% | 12.08B | |
| +30.23% | 11.98B |
- Stock Market
- Equities
- BVX Stock
- Financials BiVictriX Therapeutics Plc